Cubist Pharmaceuticals Inc (CBST) financial statements (2020 and earlier)

Company profile

Business Address 65 HAYDEN AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments579976
Cash and cash equivalents91104
Short-term investments488872
Receivables12393
Inventory, net of allowances, customer advances and progress billings5842
Inventory5842
Prepaid expense and other current assets31
Deferred tax assets52 
Other undisclosed current assets5814
Total current assets:8701,157
Noncurrent Assets
Property, plant and equipment178166
Long-term investments and receivables 3
Long-term investments 3
Intangible assets, net (including goodwill)1,104267
Goodwill383114
Intangible assets, net (excluding goodwill)721153
Other noncurrent assets98
Prepaid expense and other noncurrent assets66
Other undisclosed noncurrent assets896273
Total noncurrent assets:2,276775
TOTAL ASSETS:3,1461,932
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities277209
Accounts payable3246
Accrued liabilities245164
Deferred revenue and credits67
Other liabilities74
Other undisclosed current liabilities2039
Total current liabilities:311259
Noncurrent Liabilities
Long-term debt and lease obligation1,041466
Long-term debt, excluding current maturities1,041466
Liabilities, other than long-term debt437179
Deferred revenue and credits3134
Deferred tax liabilities, net358103
Liability for uncertainty in income taxes1614
Other liabilities3228
Other undisclosed noncurrent liabilities(37)38
Total noncurrent liabilities:1,441683
Total liabilities:1,752942
Stockholders' equity
Stockholders' equity attributable to parent1,394991
Common stock00
Additional paid in capital1,362941
Accumulated other comprehensive income (loss)0(0)
Retained earnings3150
Total stockholders' equity:1,394991
TOTAL LIABILITIES AND EQUITY:3,1461,932

Income statement (P&L) ($ in millions)

12/31/2013
12/31/2012
Revenues1,054926
Cost of revenue
(Cost of Goods and Services Sold)
(260)(230)
Gross profit:794696
Operating expenses(847)(511)
Other undisclosed operating income7952
Operating income:26237
Nonoperating expense(70)(38)
Other nonoperating expense(35)(8)
Interest and debt expense(38)(33)
Other undisclosed income from continuing operations before equity method investments, income taxes3833
Income (loss) from continuing operations before income taxes:(44)200
Income tax expense (benefit)25(46)
Net income (loss) available to common stockholders, basic:(19)154
Other undisclosed net income available to common stockholders, diluted 17
Net income (loss) available to common stockholders, diluted:(19)171

Comprehensive Income ($ in millions)

12/31/2013
12/31/2012
Net income (loss):(19)154
Comprehensive income (loss):(19)154
Other undisclosed comprehensive income, net of tax, attributable to parent00
Comprehensive income (loss), net of tax, attributable to parent:(18)154

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: